Data Insights

Azacitidine by Bristol-Myers Squibb for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval

Azacitidine is under clinical development by Bristol-Myers Squibb and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According...

Likelihood of Approval and Phase Transition Success Rate Model - Azacitidine in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)

Data Insights

Azacitidine by Bristol-Myers Squibb for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

Azacitidine is under clinical development by Bristol-Myers Squibb and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...

Likelihood of Approval and Phase Transition Success Rate Model - Azacitidine in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

Data Insights

Azacitidine by Bristol-Myers Squibb for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

Azacitidine is under clinical development by Bristol-Myers Squibb and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Azacitidine in Diffuse Large B-Cell Lymphoma

Data Insights

Azacitidine by Bristol-Myers Squibb for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval

Azacitidine is under clinical development by Bristol-Myers Squibb and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Azacitidine in Pancreatic Ductal Adenocarcinoma

Data Insights

Azacitidine by Bristol-Myers Squibb for Polycythemia Vera: Likelihood of Approval

Azacitidine is under clinical development by Bristol-Myers Squibb and currently in Phase II for Polycythemia Vera. According to GlobalData, Phase...

Data Insights

Azacitidine by Bristol-Myers Squibb for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis): Likelihood of Approval

Azacitidine is under clinical development by Bristol-Myers Squibb and currently in Phase II for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis). According...

Data Insights

Azacitidine by Bristol-Myers Squibb for Essential Thrombocythemia: Likelihood of Approval

Azacitidine is under clinical development by Bristol-Myers Squibb and currently in Phase II for Essential Thrombocythemia. According to GlobalData, Phase...

Data Insights

Azacitidine by Bristol-Myers Squibb for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval

Azacitidine is under clinical development by Bristol-Myers Squibb and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...